Bystander Activation of T Cells May Be Cause of Persistent Arthritis in Lyme Disease
“One of the clinical problems with Lyme disease infection is that there’s a small group of patients who continue to display symptoms, including arthritis symptoms, following what should be an effective treatment of antibiotics,” said Janis J. Weis, PhD, a professor of pathology at University of Utah Health, and a study author.
Dr. Weis said these symptoms persist in some patients even after there’s no longer evidence of an active infection with Borrelia burgdorferi, the bacteria that causes Lyme disease.
The investigators now think they know how it’s happening. They have identified a T cell receptor that interacts with surface molecules on B. burgdorferi. According to the study, this interaction causes bystander activation of T cells, which in turn causes the T cells to produce inflammatory molecules that lead to arthritis symptoms around the joints.
Those activated T cells can continue to interact with residual bacteria long after the initial tick bite, meaning some patients continue to feel symptoms like arthritis.
To get to those results, Dr. Weis and colleagues first had to find a suitable animal model, as reliable animal markers to study the inflammatory response had not existed until now. However, Dr. Weis stated that students in her lab realized that a specific set of mice—those lacking the anti-inflammatory molecule IL-10—had the same kinds of sustained inflammatory responses that were so troublesome in the small subset of Lyme disease patients with persistent arthritis.
Graduate student, Sarah Whiteside, the study’s first author, monitored these IL-10-deficient mice for more than 4 months post infection with B. burgdorferi.
“Sarah demonstrated that even 18 weeks after infection, the arthritis was still severe and there was a tremendous amount of joint inflammation in the joint tissue, but no evidence of bacteria in the joint tissue,” Weis told Contagion®.
“Instead of activating a very small, specific set of T cells, it causes this global activation of immune cells,” Ms. Whiteside said.
The implications of the study are multiple. Ms. Whiteside shared that a next step will be to test the theory in humans to confirm whether bystander activation is also contributing to lingering symptoms in human patients with Lyme disease.
At the same time, identification of the IL-10 deficient mouse model could spark additional research and new therapies, such as a therapy to short-circuit T cell activation so as to mitigate the risk of persistent arthritis.
Further research may look into whether it is possible to identify which patients are most likely to have persistent symptoms. Thus far, we have no way of reliably identifying those patients, Dr. Weis stated, but she noted that research from Allen Steere, MD, of Massachusetts General Hospital, has suggested that certain genetic markers seem to be more common in patients who develop persistent arthritis with Lyme disease. Those markers are similar to the markers associated with rheumatoid arthritis (RA), she continued. However, that connection doesn’t appear to be found 100% of the time.
“It’s not an all-or-nothing kind of association,” stated Dr. Weis.
“Maybe drugs that are used to treat RA or drugs that can temporarily suppress the immune response could be applicable for this persistent arthritis,” added Ms. Whiteside.
Interesting article but a few points to consider:
- The group that continues to have symptoms isn’t small. There’s a lot of us! Microbiologist Holly Ahern states current research estimates 60% of patients suffer with chronic symptoms: https://madisonarealymesupportgroup.com/2019/02/25/medical-stalemate-what-causes-continuing-symptoms-after-lyme-treatment/
- What is their definition of “effective treatment?” There is heated debate on that topic: https://madisonarealymesupportgroup.com/2017/05/05/the-reality-of-lyme-disease-not-just-two-camps-anymore/ If they are pushing the 21 days of doxycycline rubbish, current research has completely refuted it: https://madisonarealymesupportgroup.com/2018/10/30/study-shows-lyme-msids-patients-infected-with-many-pathogens-and-explains-why-we-are-so-sick/ The issues of pleomorphism (shapeshifting), coinfections (other pathogens), biofilm, pathogen persistence, and effective drug blood levels must be dealt with.
- Just because they haven’t found Bb, doesn’t mean it’s not there. We know Bb travels everywhere within the body. Until they are able to test every organ of the body, they are only stating they didn’t find it in the ONE place they looked. Blood tests for Bb are abysmal. Bb doesn’t hang out in the blood. It’s a stealth organism that hides out and changes form. One of the hallmarks of Lyme is it migrates.
- Her suggestion of immunopressive drugs will worsen many due to persistent infection. LLMD’s have long known that immunosuppressive drugs make infection worse: http://www.lymenet.de/literatur/steroids.htm (Please remember not all steroids are bad. There are anabolic and there are catabolic. Big difference.)
- This article again highlights the importance of post-mortem studies needed to determine persistent/active infection: https://madisonarealymesupportgroup.com/2018/04/13/chronic-lyme-post-mortem-study-needed-to-end-the-lyme-wars/
- http:// This short 7 min. video from Envita explains:The helper T-cells come along and pick up the processed antigen off the dendritic cell and then passes it along to the killer T cells. The Killer T cells follow the spirochete throughout the body and proceeds to destroy healthy tissues and organs because they can’t differentiate between the antigen of the spirochete and the antigen of healthy tissue. As the killer T cells come into contact with the antigen on the healthy tissue it becomes inflamed and destroys healthy tissue and is autoimmune in nature.
This video was made in 2008. I guess the authors missed it, as well as this groundbreaking study the video is based upon: https://www.scirp.org/Journal/PaperInformation.aspx?PaperID=52890#.VK2lFivF8WI